1 COVID-19 severity is associated with immunopathology and

2 multi-organ damage

3

4 Running Title: Insight of pathophysiology of COVID-19

5

6	Yan-Mei Chen ^{1,4} ,	Yuanting Zheng ^{1, 4} ,	Ying Yu ^{1, 4} ,	Yunzhi Wang ^{1, 4} ,	, Qingxia Huang ^{1, 4} , Feng
---	-------------------------------	----------------------------------	---------------------------	-------------------------------	--

7 Qian^{1, 4}, Lei Sun^{2, 4}, Zhi-Gang Song¹, Ziyin Chen¹, Jinwen Feng¹, Yanpeng An¹, Jingcheng

8 Yang¹, Zhenqiang Su¹, Shanyue Sun¹, Fahui Dai¹, Qinsheng Chen¹, Qinwei Lu¹, Pengcheng

9 Li¹, Yun Ling¹, Zhong Yang¹, Huiru Tang¹, Leming Shi¹, Li Jin¹, Edward C. Holmes³, Chen

```
10 Ding<sup>1</sup>*, Tong-Yu Zhu<sup>1</sup>*, Yong-Zhen Zhang<sup>1</sup>*
```

11

¹Shanghai Public Health Clinical Center, State Key Laboratory of Genetic Engineering,

13 School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China.

¹⁴ ²Institute of Developmental Biology and Molecular Medicine, Fudan University, Shanghai,

15 China.

¹⁶ ³Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and

17 Environmental Sciences and School of Medical Sciences, The University of Sydney, Sydney,

18 New South Wales, Australia.

19

⁴These authors contributed equally: Yan-Mei Chen, Yuanting Zheng, Ying Yu, Yunzhi Wang,

21 Qingxia Huang, Feng Qian, Lei Sun

- 22 *Correspondence to: Yong-Zhen Zhang, Email: <u>zhangyongzhen@shphc.org.cn;</u>
- 23 Tong-Yu-Zhu, Email: <u>zhutongyu@shphc.org.cn;</u> Chen Ding, Email: chend@fudan.edu.cn.

24 Abstract

25	COVID-19 is characterised by dysregulated immune responses, metabolic dysfunction and
26	adverse effects on the function of multiple organs. To understand how host responses
27	contribute to COVID-19 pathophysiology, we used a multi-omics approach to identify
28	molecular markers in peripheral blood and plasma samples that distinguish COVID-19
29	patients experiencing a range of disease severities. A large number of expressed genes,
30	proteins, metabolites and extracellular RNAs (exRNAs) were identified that exhibited strong
31	associations with various clinical parameters. Multiple sets of tissue-specific proteins and
32	exRNAs varied significantly in both mild and severe patients, indicative of multi-organ damage.
33	The continuous activation of IFN-I signalling and neutrophils, as well as a high level of
34	inflammatory cytokines, were observed in severe disease patients. In contrast, COVID-19 in
35	mild patients was characterised by robust T cell responses. Finally, we show that some of
36	expressed genes, proteins and exRNAs can be used as biomarkers to predict the clinical
37	outcomes of SARS-CoV-2 infection. These data refine our understanding of the
38	pathophysiology and clinical progress of COVID-19 and will help guide future studies in this
39	area.
40	
41	Key worlds: SARS-CoV-2 / COVID-19 pathophysiology / multiple organ damage /

- 42 immunopathogenesis / multi-omics
- 43

44 Introduction

45	Coronaviruses (famil	y Coronaviridae) are a diverse	group of positi	ve-sense single-stranded
----	----------------------	-----------------	-----------------	-----------------	--------------------------

- 46 RNA viruses with enveloped virions (Cui et al., 2019; Masters and Perlman, 2013).
- 47 Coronaviruses are well known due to the emergence of Severe Acute Respiratory Syndrome
- 48 (SARS) in 2002–2003 and Middle East Respiratory Syndrome (MERS) in 2012, both of which
- 49 caused thousands of cases in multiple countries (Bermingham et al., 2012; Cui et al., 2019;
- 50 Ksiazek et al., 2003). Coronaviruses naturally infect a broad range of vertebrate hosts
- 51 including mammals and birds (Cui et al., 2019). As coronavirus primarily target epithelial cells,
- 52 they are generally associated with gastrointestinal and respiratory infections (Cui et al., 2019;
- 53 Masters and Perlman, 2013). In addition, they cause hepatic and neurological diseases of
- 54 varying severity (Masters and Perlman, 2013).
- 55 The world is currently experiencing a disease pandemic (COVID-19) caused by a newly
- identified coronavirus called SARS-CoV-2 (Wu et al., 2020a). At the time of writing, there

57 have been more than 6 million cases of SARS-CoV-2 and over 387,000 deaths globally

- 58 (WHO, 2020). The disease leads to both mild and severe respiratory manifestations, with the
- 59 latter prominent in the elderly and those with underlying medical conditions such as

60 cardiovascular and chronic respiratory disease, diabetes, and cancer (Guan et al., 2020). In

- 61 addition to respiratory syndrome, mild gastrointestinal and/or cardiovascular symptoms as
- 62 well as neurological manifestations have been documented in hospitalized COVID-19 patients
- 63 (Mao et al., 2020). Combined, these data point to multiple organ failures, and hence that
- 64 COVID-19 pathogenesis is complex, especially in patients experiencing severe disease.

65	It is believed that SARS-COV-2 is able to use angiotensin-converting enzyme 2 (ACE 2)
66	as a receptor for cell entry (Zheng et al., 2020; Zhou et al., 2020b). ACE2 is attached to the
67	outer surface (cell membranes) of cells in the lungs, arteries, heart, kidney, and intestines
68	(Hamming et al., 2004). Additionally, ACE2 is expressed in Leydig cells in the testes (Jiang et
69	al., 2014) and neurological tissue (Baig et al., 2020). As such, it is possible that these organs
70	might also be infected by SARS-CoV-2. The host immune response to SARS-CoV-2 may also
71	impact pathogenicity, resulting in severe tissue damage and, occasionally, death. Indeed,
72	several studies have reported lymphopenia, exhausted lymphocytes and cytokine storms in
73	COVID-19 patients (Blanco-Melo et al., 2020; Cao, 2020). Numerous clinical studies have
74	also observed the elevation of lactate dehydrogenase (LDH), IL-6, troponin I, inflammatory
75	markers and D-dimer in COVID-19 patients (Wang et al., 2020b; Zhou et al., 2020a). However,
76	despite the enormous burden of morbidity and mortality due to COVID-19, we know little
77	about its pathophysiology, even though this establishes the basis for successful clinical
78	practice, vaccine development and drug discovery.
79	Using a multi-omics approach employing cutting-edge transcriptomic, proteomic and
80	metabolomic technologies we identified significant molecular alterations in patients with
81	COVID-19 compared to uninfected controls in this study. Our results refine the molecular view
82	of COVID-19 pathophysiology associated with disease progression and clinical outcome.
83	

84 Results

85 Patient cohort and clinical characters

86	We studied 66 clinically diagnosed and laboratory confirmed COVID-19 patients hospitalized
87	at the Shanghai Public Health Clinical Center, Shanghai, China between January 31st and
88	April 7th, 2020 (Fig. 1A, Tables S1 and S2). At the time of writing, 55 (49 mild and 6 severe) of
89	the 66 patients have recovered and been discharged following treatment, while five patients
90	(1 mild and 4 severe) remain in the hospital and are receiving ongoing treatment.
91	Unfortunately, six patients (all severe) died.
92	Molecular variation associated with COVID-19 pathophysiology
93	Serial blood and throat swab samples were collected from all patients, as well as from 17
94	healthy volunteers. To determine whether COVID-19 pathophysiology was associated with
95	particular molecular changes, a total of 23,373 expressed genes, 9,439 proteins, 327
96	metabolites and 769 exRNAs were examined using a multi-omics approach combining
97	transcriptomics, proteomics, and metabolomics (Fig. 1B). Compared with healthy controls,
98	mild and severe patients had significantly different expression patterns (higher or lower) in
99	6.79% and 26.0% of expressed genes, 52.1% and 51.7% of proteins, 7.34% and 15.6% of
100	metabolites and 39.9% and 20.5% of exRNAs, respectively (Fig. 1C, Tables S3-S6).
101	Significant differences in the principal component 1 (PC1), PC2 and/or PC3 between healthy
102	controls, mild and severe COVID-19 patients were observed (Figs. 2A and S1A). Remarkably,
103	there were significant correlations between multi-omics data and classical blood and
104	biochemical parameters (Fig. 2B), suggesting that the molecular changes identified directly
105	impact the pathophysiology of COVID-19.

106	The correlation between molecular variation and COVID-19 pathophysiology was best
107	reflected in the proteomic analysis (Fig. 2). Specifically, there was significant downregulation
108	in the tricarboxylic acid cycle (TCA) and glycolytic pathways in both mild and severe patients
109	compared to healthy controls (Figs. 2C and S1B). However, the hypoxia-inducible factors
110	(HIF-1) signaling pathways and well-known host defense pathways (e.g., T cell receptor
111	signaling pathway, ISG15 antiviral signaling pathway) were elevated in these patients (Figs.
112	2C and S1B). Additionally, we identified 14 co-expression groups ("modules") of proteins that
113	were highly correlated to clinical parameters (Fig. 2D). Module 1, comprising 12 proteins, was
114	strongly associated with activated partial thromboplastin time (APTT) (Fig. 2E), with their
115	downregulated expression likely indicating higher APTT values. In contrast, levels of plasma
116	IL-6 and IL-10 in patients were positively correlated with the expression of proteins in module
117	15 (Fig. 2F). Notably, correlations between the proteins in these modules were also identified,
118	suggesting that proteins may interact in defining clinical outcome (Figs. S2C and S2D). In
119	addition to proteins, lipoprotein variation was also significantly correlated with immune
120	changes including IgG, monocytes and procalcitonin (Fig. 2B). Combined, these data reveal a
121	significant association between specific molecular variations and COVID-19 pathophysiology.
122	Tissue damage caused by SARS-CoV-2
123	Recent data suggests that SARS-CoV-2 infection is associated with multi-tissue injury and
124	organ damage (Wu et al., 2020b; Zheng et al., 2020). Compared to healthy controls, intensive
125	alteration of tissue-enhanced proteins were observed in all COVID-19 patients, suggestive of

126 multiple organ dysfunction including the lung, liver, brain, testis and intestine (Figs. 3A and 3I).

127	Notably, the majority of proteins related to organ function were downregulated in COVID-19
128	patients (Fig. 3B). As expected, lung-enhanced proteins varied significantly in the plasma of
129	both mild and severe patients. Likely because lung-enhanced proteins are not rich in the
130	human protein atlas, the lung-enhanced proteins in either mild or severe patients did not
131	achieve the top rank. Nevertheless, lung abnormality was reflected in the activation of the
132	HIF-1 signaling pathway and reactive oxygen species metabolic processes in all patients (Fig.
133	3D). Liver- and brain-enhanced proteins also varied significantly, followed by those from the
134	testis, intestine and other organs, suggesting that these organs might also be seriously
135	affected (Fig. 3A). Severe brain dysfunction was reflected in the significant decline of
136	brain-enhanced proteins regulating neurotransmitter synthesis, neurotransmitter transport,
137	and the numbers of neurotransmitter receptors, as well as a significant decrease in proteins
138	including ENO1, MBP and NEFM that are known biomarkers to reflect brain dysfunction (Figs.
139	3C and 3F). Liver-enhanced proteins, that regulate the transportation of sterol and cholesterol,
140	were downregulated, while those involved in acute inflammatory response were elevated in
141	both mild and severe patients (Fig. 3E). Testis-enhanced proteins involved in the cell cycle and
142	cell proliferation were upregulated in all male patients, although proteins (e.g. YBX2)
143	associated with reproduction were significantly downregulated. Heart specific proteins related
144	to cardia muscle contraction and oxidative reduction were reduced in COVID-19 patients (Fig.
145	3H). Finally, variation in tissue-enhanced proteins was also associated with COVID-19 severity.
146	For example, brain-enhanced proteins enriched in tubulin accumulation were upregulated in
147	mild disease patients, indicating multiple neuron cell apoptosis in these patients. However,

proteins significantly upregulated in severe patients were enriched in liver steatosis AOP and
in multi-drug resistance factors (Figs. S2A and S2B).

150	Organ dysfunction was also reflected in the relative proportion of different cell
151	populations. We identified 16 cell types whose abundance changed significantly following
152	virus infection (Fig. 3F). For example, the set of proteins expressed by alveolar type 1/2
153	epithelial cells (AT1 and AT2) were significantly downregulated in all patients (Fig. 3G). In
154	addition, the majority of tissue-injury related exRNAs across all tissues showed differential
155	expression, including lung (55 in 92 pre-identified, p <0.0001), kidney (14 in 22, p <0.0001),
156	liver (17 in 22, <i>p</i> <0.0001), brain (8 in 16, <i>p</i> =0.0016) and heart (5 in 6, <i>p</i> <0.0001) (Fig. S2C).
157	Furthermore, a large proportion of tissue-injury related exRNAs were expressed differently in
158	mild and severe patients in most tissues analyzed (30/92 in lung, 10/22 in kidney, 8/22 in liver
159	and 3/6 in heart), except brain (1/16) (data not shown). Together, our data indicate that
160	COVID-19 causes adverse functions in multiple organs including lung damage.
161	Immunopathological changes in COVID-19 patients
162	Immune responses can cause severe damage to the cells or tissues that defend hosts against
163	viral infection (Baseler et al., 2017; Cicchese et al., 2018; Newton et al., 2016). Analysis of
164	whole blood transcriptomic data revealed that gene sets, including an antiviral IFN signature
165	(M75 module), were enriched at the first sampling timepoint (Fig. 4A, Table S7). Notably, IFN
166	signaling was continuously activated in severe patients during the entire period of

- 167 hospitalization (Fig. 4A), while negative regulators of innate immune signaling (e.g. TRIM59,
- 168 USP21 and NLRC3) were downregulated (Fig. S3A). Additionally, significant increases of IL-6,

169	IL-8 and IL-10 levels were detected in severe patients compared to mild patients (Figs. 2F
170	and S3B). Combined, these data suggest that the continuous activation of IFN-I signaling and
171	a high level of inflammatory cytokines likely impact COVID-19 immunopathology.
172	Higher neutrophil counts were observed in severe patients but not in mild patients during
173	hospitalization (Fig. S3C). Examination of the neutrophil transcriptomic signatures revealed
174	that excessive neutrophil activation was associated with severe rather than mild disease.
175	These markers involved those utilized in neutrophil chemotaxis, activation and migration (Fig.
176	S3D). Notably, genes encoding molecules associated with neutrophil extracellular traps
177	(NETs) were significantly upregulated in severe disease patients (Fig. 4B). As excess NETs
178	formation can lead to tissue damage (Kruger et al., 2015), our data imply that the excessive
179	activation of neutrophils may contribute to COVID-19 pathogenesis.
180	As in the case of influenza viruses that can be cleared by strong T cell responses (van de
181	Sandt et al., 2014; Wang et al., 2015), SARS-CoV-2 immunity in mild patients was
182	characterized by a robust T cell response, reflected in T cell signaling activation (M7.3 module,
183	M35.1 module) and T cell differentiation (M19 module) on admission, followed by subsequent
184	rapid reduction (Fig. 4A). However, severe patients lost ~59.1% of their total T cell population,
185	62.3% of their CD4 T cells and 52.8% of their CD8 T cells. Importantly, the CD4 T cell
186	population gradually recovered in the severe-survivors compared to the severe-fatality group
187	(Fig. S3E). Additionally, T cells in the survivors were primed by dendritic cells and expressed
188	high levels of IFNG and GZMB (Fig. 4C). T cell dysfunction was observed in the severe group,
189	which could in part be due to an inhibitory status based on the expression levels of multiple 9

190	exhaustion markers (Fig. S3F). Strikingly, the severe disease group had a greater abundance
191	of ARG1 (Fig. S3G). Finally, the mild group had higher TCR diversity than the severe group
192	(Fig. S3H). In sum, our data suggest that the T cell response is indispensable to successful
193	host defense against SARS-CoV-2.
194	Finally, we investigated the immune signatures associated with poor COVID-19
195	prognosis. Notably, KEGG functional analysis revealed that gene sets of the "IL-17 signaling
196	pathway" were significantly enriched in the severe-fatality group. Further analysis of the
197	signature components revealed that p38 MAPK activation was dominant in fatal cases, while
198	higher levels of IL13 and IFNG were present in survivors (Fig. 4D). These gene signatures
199	might contribute to greater neutrophil influx (CXCL2 and CXCL6) and inflammation (S100A8),
200	and could be detrimental in the severe disease group (Fig. 4E).
200 201	and could be detrimental in the severe disease group (Fig. 4E). Comprehensive changes in lipoprotein metabolism in COVID-19 patients
200 201 202	and could be detrimental in the severe disease group (Fig. 4E). Comprehensive changes in lipoprotein metabolism in COVID-19 patients To reveal metabolic changes in COVID-19 patients, we quantified 348 metabolite parameters
200 201 202 203	and could be detrimental in the severe disease group (Fig. 4E). Comprehensive changes in lipoprotein metabolism in COVID-19 patients To reveal metabolic changes in COVID-19 patients, we quantified 348 metabolite parameters in small metabolites, lipoprotein subclasses and their compositional components. The PCA
200 201 202 203 204	and could be detrimental in the severe disease group (Fig. 4E). Comprehensive changes in lipoprotein metabolism in COVID-19 patients To reveal metabolic changes in COVID-19 patients, we quantified 348 metabolite parameters in small metabolites, lipoprotein subclasses and their compositional components. The PCA scores plot revealed an obvious metabolomic trajectory from mild to severe COVID-19, and
200 201 202 203 204 205	and could be detrimental in the severe disease group (Fig. 4E). Comprehensive changes in lipoprotein metabolism in COVID-19 patients To reveal metabolic changes in COVID-19 patients, we quantified 348 metabolite parameters in small metabolites, lipoprotein subclasses and their compositional components. The PCA scores plot revealed an obvious metabolomic trajectory from mild to severe COVID-19, and gradually away from healthy controls (Fig. 5A). Such group-clustering patterns were
200 201 202 203 204 205 206	and could be detrimental in the severe disease group (Fig. 4E). Comprehensive changes in lipoprotein metabolism in COVID-19 patients To reveal metabolic changes in COVID-19 patients, we quantified 348 metabolite parameters in small metabolites, lipoprotein subclasses and their compositional components. The PCA scores plot revealed an obvious metabolomic trajectory from mild to severe COVID-19, and gradually away from healthy controls (Fig. 5A). Such group-clustering patterns were independently confirmed by PCA scores plots from all NMR-detectable metabolite signals, all
200 201 202 203 204 205 206 207	and could be detrimental in the severe disease group (Fig. 4E). Comprehensive changes in lipoprotein metabolism in COVID-19 patients To reveal metabolic changes in COVID-19 patients, we quantified 348 metabolite parameters in small metabolites, lipoprotein subclasses and their compositional components. The PCA scores plot revealed an obvious metabolomic trajectory from mild to severe COVID-19, and gradually away from healthy controls (Fig. 5A). Such group-clustering patterns were independently confirmed by PCA scores plots from all NMR-detectable metabolite signals, all MS-detectable signals for lipids, and hydrophilic molecules in plasma samples (Figs.
200 201 202 203 204 205 206 207 208	and could be detrimental in the severe disease group (Fig. 4E). Comprehensive changes in lipoprotein metabolism in COVID-19 patients To reveal metabolic changes in COVID-19 patients, we quantified 348 metabolite parameters in small metabolites, lipoprotein subclasses and their compositional components. The PCA scores plot revealed an obvious metabolomic trajectory from mild to severe COVID-19, and gradually away from healthy controls (Fig. 5A). Such group-clustering patterns were independently confirmed by PCA scores plots from all NMR-detectable metabolite signals, all MS-detectable signals for lipids, and hydrophilic molecules in plasma samples (Figs. S4A-S4D). Our data therefore indicate that a concentration of changes in plasma metabolites

210	Further statistical analyses highlighted the major changes in the levels of lipoprotein
211	sub-classes and their compositional components including LDL1 (L1TG), LDL4, VLDL5,
212	HDL1 and HDL4 (Figs. 5C and S4E). Compared with healthy controls, the level of
213	triglycerides (TG) in LDL1 and free cholesterol (FC) in all VLDL5 lipids were significantly
214	elevated in both mild and severe patients, while there were significant decreases in LDL4 and
215	LDL5, cholesterol in LDL, cholesterol esters in VLDL5, Apo-A2 in both HDL and nascent HDL,
216	FC in HDL1 together with total cholesterol and phospholipids (PL). Interestingly, HDL4 and its
217	components had significant lower levels in severe patients. Compared with mild patients,
218	L1TG and PL in HDL1 was increased in severe patients, while cholesterol in HDL1 and HDL2,
219	HDL4 and its components decreased (Fig. S4F). Fortunately, most of these lipoproteins
220	recovered following patients discharge (Figs. 5B, 5C and S4D).
221	The levels of some key proteins involved in lipoprotein metabolism, including the
222	soluble low-density lipoprotein receptor (sLDLR), lecithin-cholesterol acyltransferase (LCAT)
223	and the cholesteryl-ester transfer protein (CETP), were significantly reduced in mild and
224	severe COVID-19 patients than those in healthy controls (Figs. 5D and 5E). Additionally,
225	enzymes such as ACO2, IDH, OGDH, DLD, SDH and MDH in the TCA cycle were lower in
226	COVID-19 patients compared to healthy controls, while the enzymes central to fatty acid
227	synthesis (Acetyl coenzyme A carboxylase [ACAC] and Fatty acid synthetase [FASN]) were
228	elevated. Finally, significant concurrent elevations in plasma lactate and LDH were
229	observable in patients compared to healthy controls (Figs. 5E, S4G and S4H). In sum, these

230 data reveal the dysregulation in lipoprotein metabolism, glycolysis and TCA cycle during

231 SARS-CoV-2 infection.

232	Viral load is associated with disease prognosis of severe COVID-19 patients
233	The severity and clinical outcome of COVID-19 were also associated with viral load. Overall,
234	SARS-CoV-2 RNA loads on admission were significantly higher in the throat swabs of the five
235	fatal cases compared to those who survived (mean, 1.26×10^5 vs 3.98×10^3 copies/mL,
236	respectively; $p = 0.04$) (Fig. 6A). Although viral load declined during the period of
237	hospitalization in both survival and fatal cases, it remained elevated in fatal cases compared
238	to survivors.
239	Estimation of the correlation coefficient between viral load and protein expression
240	revealed that proteins participating in antiviral processes, including the TCR and BCR
241	signaling pathway, were positively associated with viral load changes in severe-survivors.
242	Additionally, proteins participating in viral life cycle processes, including viral messenger RNA
243	synthesis and innate immune responses, were only positively associated with viral load
244	changes in the severe-fatal group (Fig. 6E). Notably, proteins (e.g., FASN, ACSS2, CPT1A,
245	HADHB) involved in pathways including mitochondrial function, lipid metabolic process,
246	steroid hormone process and TCA cycle were continuously upregulated in the severe-survivor
247	compared to the severe-fatal group (Figs. 6B and 6C). However, this upregulation was only
248	observed during the early stage following admission in the severe-fatal group. Surprisingly,
249	proteins related to viral life cycle, viral RNA synthesis, oxidative stress (e.g., EIF, EIFB,
250	RPL19, SLCA24), were downregulated in the several-survivor cases following admission, but 12

- 251 maintained high levels in the severe-fatal patients (Figs. 6B and 6D). Hence, SARS-CoV-2
- 252 may exploit host resources over the duration of its infection.

253 Biomarkers predictive of clinical outcomes of COVID-19 patients

- As many molecules associated with COVID-19 pathophysiology were identified, we
- 255 investigated whether particular molecular changes could be used as biomarkers to predict
- clinical outcomes. Using an unsupervised PCA, the exRNA, mRNA, proteomics and the
- 257 corresponding clinical covariate data sets across all time-points, or a subset from the first
- time-point, clustered into three clinical phenotypes: (i) samples from healthy controls; (ii)
- samples from COVID-19 patients with a good prognosis; and (iii) samples from COVID-19
- 260 patients with a poor prognosis (Methods; Fig. 7A). Given this, prognostic classification models
- 261 were constructed. Predictive models based on all four types of data worked well, especially
- those utilizing the clinical covariates and the proteomic data (Fig. S5), suggesting that all four
- types of data collected at admission contain key prognostic information.
- 264 In addition, we identified robust predictive models and prognostic biomarkers from
- each of the four types of data using a previously described approach (Shi et al., 2010) (Figs.
- 266 7B and 7C). One or two features (expressed genes, proteins, exRNAs, and biochemical
- 267 parameters) in each data set were able to clearly separate patients into two groups
- characterized by different prognoses (Figs. 7D-7I). Poor prognosis was associated with
- increased levels of D-dimer (p=0.004) and fibrinogen degradation products (FDP; p=0.02),
- and with a decrease in F13A1 expression (p<0.002; Figs. 7H and 7I), suggesting that blood
- clotting status may be one of the key factors to monitor in COVID-19 progression. For the

272	mRNA-based model, poor prognosis was associated with lower levels of CD3E and higher
273	levels of OLAH, and hence highly concordant with immune responses in COVID-19 patients
274	(Fig. 7E). Additionally, exRNA-based predictors included members of the let-7 family (Figs.7D
275	and 7E). Finally, the protein-based models highlighted features enriched in extracellular
276	exosomes, lipoprotein metabolic processes, innate immune responses, and blood
277	coagulation (Figs. 7G and 7H).
278	
279	Discussion
280	The COVID-19 pandemic has had a profound impact on a global scale (WHO, 2020). Despite
281	the enormous burden or morbidity and mortality due to COVID-19, we know little about its
282	pathophysiology, even though this establishes the basis for successful clinical practice,
283	vaccine development and drug discovery. Current clinical practice may be unable to provide a
284	precision supportive therapy when a novel disease like COVID-19 emerges, in part explaining
285	the high case fatality rates often observed at the beginning of outbreaks (Alonso et al., 2019).
286	We used a multi-omics approach to identify numerous expressed genes, proteins,
287	metabolites and exRNAs from COVID-19 patients with a range of disease severities, and that
288	were significantly correlated with key clinical features as well as to classic blood and
289	biochemical parameters (Fig. 2). These data therefore provide a comprehensive molecular
290	view of the pathophysiology of COVID-19. Finally, based on our multi-omics data (Fig. S6),
291	mild and severe COVID-19 cases may need different therapeutic strategies.

292	COVID-19 severity and clinical outcome was significantly associated with multi-organ
293	damage. Due to the widespread presence of ACE2 in humans (Chai et al., 2020; Chen et al.,
294	2020b; Fan et al., 2020; Hamming et al., 2004; Zou et al., 2020), SARS-CoV-2 is able to infect
295	many organs (Wadman et al., 2020). In addition to pneumonia (Wu et al., 2020a; Zhou et al.,
296	2020b), several clinical studies have reported mild gastrointestinal, cardiovascular symptoms
297	and neurological manifestations in hospitalized COVID-19 patients (Baig, 2020; Chen et al.,
298	2020a; Guan et al., 2020; Mao et al., 2020; Xiang et al., 2020; Xu et al., 2020).
299	Histopathologic investigation has also described damage in other organs in addition to the
300	lung (Barton et al., 2020; Cai et al., 2020; Wadman et al., 2020; Wang et al., 2020c). The
301	molecular data generated here support the occurrence of damage in multiple organs including
302	lung, liver, brain, heart in COVID-19 patients, and also identify damage in other organs
303	including the testis (Fig. 3). In the case of brain and testis damage, a key issue is how
304	SARS-CoV-2 is able to cross the blood-brain or the blood-testis barriers? One possibility
305	might be that heparin was prescribed for coaggregation problems commonly observed in
306	some COVID-19, even though it increases permeability (Gautam et al., 2001; Lin et al., 2020;
307	Oschatz et al., 2011). More importantly, the alteration (up- or down-regulated) of
308	tissue-enhanced proteins and tissue-damage related exRNAs are significantly correlated with
309	clinical severity and outcome.
310	SARS-CoV-2 infection results in acute lung injury (ALI) in patients, with ground-glass
311	opacity in most computed tomography (CT) reports from our facility and in other hospitals

312 (Chen et al., 2020a; Zhou et al., 2020b; Zhu et al., 2020). Autopsy disclosed histologic

313	changes in lungs included edema, fibrinous/proteinaceous exudates, hyperplastic
314	pneumocytes, patchy inflammation, multinucleated giant cells and diffuse alveolar damage
315	(Barton et al., 2020; Tian et al., 2020). The data generated here revealed that the number of
316	AT1 and AT2 cells reduced significantly in severe patients, suggesting destruction of the
317	alveolar epithelium (Fig. 3F), which in turn will lead to the accumulation alveolar fluid and
318	hence cause hypoxia (Vadász and Sznajder, 2017). In addition, we also noted that HIF1a
319	signaling was modified which may further worsen ALI (Dada et al., 2003). Thus, our molecular
320	data suggest that removal of excess alveolar fluid and the restoration of alveolar structure will
321	be of major clinical importance.
322	Our data also identified immune pathophysiology a factor that greatly impacted
323	COVID-19 clinical outcome. The innate immune response against viruses is mounted
324	immediately after a host acquires a viral infection, whereas there is a delay before the onset of
325	adaptive immunity (Murphy and Weaver, 2016). Unlike SARS-CoV and influenza virus,
326	SARS-CoV-2 may be present in patients for longer time periods, especially those with severe
327	syndrome (Du et al., 2020; Wang et al., 2020a). Several studies have reported that severe
328	COVID-19 patients experienced lymphopenia, impaired adaptive immunity, uncontrolled
329	inflammatory innate responses, and cytokine storms (Guan et al., 2020; Huang et al., 2020;
330	Qin et al., 2020; Shi et al., 2020; Wang et al., 2020b). While it is believed that T cells play an
331	important role in fighting the infection in the case of Ebola virus, influenza virus and
332	SARS-CoV (Channappanavar et al., 2014; Ruibal et al., 2016; Sridhar et al., 2013; van de

333	Sandt et al., 2014; Zhao et al., 2010), a role for T cells in SARS-CoV-2 infection not yet has
334	been determined, likely reflecting "lymphopenia" (Wang et al., 2020d; Zhou et al., 2020c).
335	Our longitudinal analyses provided evidence that patients with mild or severe symptoms
336	who succeeded in T cell mobilization promptly controlled SARS-CoV-2 infection and
337	symptoms (Figs. 2C, 4A and 4C). In contrast, those (especially severe-fatal) patients that
338	failed to mount a sound T cell response maintained a continuous pro-inflammatory response
339	and suffered from cytokine storms as well as excess NETs (Figs. 4A and 4B), both of which
340	are known to cause systematic tissue damages (Akiyama et al., 2019; Bohmwald et al., 2019).
341	In sum, our data indicate that T cells play a key role in controlling SARS-CoV-2 infection.
342	It is believed that p38 signaling, collagenase (MMP9), neutrophil chemo-attractants
343	(CXCL2 and CXCL6) and S100A8 are autoinflammation-like signatures (Cheng et al., 2019;
344	Chung, 2011; Halayko and Ghavami, 2009; Mattos et al., 2002). Remarkably, these
345	molecules were significantly upregulated in severe-fatal in comparison to mild and
346	severe-survival patients (Fig. 4D), the former of which also exhibited a persistent elevation of
347	type I interferon responses (Fig. 4A). Together, the data generated here indicate that
348	autoinflammation may amplify disease in very severe cases of COVID-19.
349	Patients will receive better and precision therapy if we are able to identify molecular
350	biomarkers associated with prognosis at the beginning of disease presentation. For example,
351	a 21-gene expression assay, which can predict clinical outcome, is used in the case of breast
352	cancer (Sparano et al., 2018). To date, however, almost no biomarkers have been used to
353	accurately predict prognosis in the case of emerging infectious diseases (Wynants et al., 17

354	2020). In this study, some of molecules identified at the beginning phase of COVID-19 were
355	significantly correlated to both classical blood and biochemical parameters, and more
356	importantly to disease severity. Based on our previous work (Shi et al., 2010; Su et al., 2014a;
357	Zhang et al., 2015), we established classification models based on each of four data types:
358	exRNAs, mRNA, proteins, and biochemical parameters. Notably, COVID-19 clinical outcomes
359	could be accurately predicted using just one or two biomarkers in each data type. In addition,
360	these biomarkers may have biological functions directly relevant to COVID-19
361	pathophysiology. For example, biomarkers let-7 family from exRNAs, OLAH and CD3E from
362	mRNAs, and C4A and C4B from proteomes concordantly revealed the importance of T-cell
363	activation and the suppression inflammatory responses. However, because of the relatively
364	small patient sample size utilized here, it is clear that more work is needed to confirm the
365	reliability and practicality these biomarkers.
366	In sum, we have identified a large number of molecules associated with COVID-19
367	pathophysiology, some of which may also be effective predictive biomarkers of clinical
368	outcome at the onset of disease. In addition, these data suggest that both distinct immune
369	responses and multi-organ damage have a major impact on COVID-19 severity and disease
370	prognosis.
371	

372 Materials and Methods

373 Study design and patient cohort

374	According to arrangements made by the Chinese Government, all adult patients in Shanghai
375	diagnosed with COVID-19 were admitted to the Shanghai Public Health Clinical Center. We
376	enrolled 66 COVID-19 patients who were treated at the Shanghai Public Health Clinical
377	Center between January 31 st and April 7 th , 2020. Based on clinical signs and the need for
378	oxygen, these patients were divided into two groups: (i) mild (50/66, 75.8%) – with clinical
379	signs of pneumonia but without oxygen support, and (ii) severe (16/66, 24.2%) – with oxygen
380	support using non-invasive ventilation, tracheal tube, tracheotomy assist ventilation or
381	extracorporeal membrane oxygenation (ECMO) (Fig. 1A and Table S1). All human samples
382	included in the present study were obtained after approval of the research by the Shanghai
383	Public Health Clinical Center Ethics Committee (YJ-2020-S018-02), together with the written
384	informed consent from each patient.
385	Sample collection and processing
386	A total of 277 blood samples, comprising 1-2 mL each, were collected by professional
387	healthcare workers over a 5-week period, with one to five sampling time points from each
388	patient. In addition, 17 blood samples were collected from 17 uninfected volunteers and
389	utilized as healthy controls. Samples were transported to the research laboratory within two
390	hours of collection. For RNA extraction, 200 μ L of whole blood was mixed with 1 mL QRIzol
391	reagent (Qiagen), followed by 15 min incubation at room temperature and subsequent
392	freezing at -80°C before total RNA extraction. The remaining whole blood samples (800-1800
393	$\mu L)$ were processed immediately to separate plasma and subsequently stored at -80°C until
394	use.

395 All clinical data were recorded b	the clinicians. COVID-19 loads were determined by
---------------------------------------	---

- 396 quantitative real-time RT-PCR using the Takara One Step PrimeScript RT–PCR kit (Takara
- 397 RR064A) as previously described (Wu et al., 2020a). Quantitative viral load tests were
- 398 performed using the BioDigital General dPCR kit (Jiangsu Saint Genomics, Cat no.

399 CSJ-3-0018).

- 400 RNA and exRNA extraction and library construction
- 401 Total RNA from whole blood samples was extracted using the RNeasy Plus Universal Mini Kit
- 402 (Qiagen) following the manufacturer's instructions. The quantity and quality of RNA solution
- 403 were assessed using a Qubit Flex fluorometer (Invitrogen) and an Agilent Bioanalyzer (Agilent
- 404 Technologies) before library construction and sequencing. RNA library construction was
- 405 performed as described using the VAHTS Universal V6 RNA-seq Library Prep Kit for Illumina
- 406 (Vazyme, China). Ribosomal, globin and RN7S RNAs were depleted using specially designed
- 407 probes (Vazyme, China).
- 408 Plasma samples were divided into aliquots and used for extracellular RNA (exRNA)

409 extraction and library construction, protein extraction and metabolomic analyses. For exRNA

- 410 library preparation, total RNA including exRNA was extracted using the miRNeasy
- 411 Serum/Plasma Advanced Kit (Qiagen). The exRNA library was prepared using the NEXTflex
- 412 Small RNA-seq Kit v3 (PerkinElmer). RNA quantity and quality were determined as
- 413 mentioned above. After final library quantification using a Qubit Flex fluorometer (Invitrogen)
- and quality control using the Bioptic Qsep100 to confirm the expected size distributions, all

- 415 libraries (RNA and exRNA) were pair-end (150-bp reads) sequenced on the Illumina
- 416 NovaSeq6000 platform (Illumina).
- 417 RNA-seq data analysis
- 418 Data processing and filtering criteria
- 419 Preliminary processing of raw reads was performed using FASTP v0.19.6 to remove adapter
- 420 sequences and obtain trimmed reads (Chen et al., 2018). The sequence
- 421 AGATCGGAAGAGCACACGTCTGAACTCCAGTCA was used as the R1 adapter sequence
- 422 while AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT was used as the R2 adapter
- 423 sequence. HISAT2 v2.1 (Pertea et al., 2016) was used for read alignment to the human
- 424 genome, build 38. Samtools v1.3.1 was used to generate intermediate result files for quality
- 425 assessment of the aligned reads by BamQC v2.0.0 (<u>https://github.com/s-andrews/BamQC</u>)
- 426 and insert size distribution analysis. The assembly of aligned reads and assessment of
- 427 expression levels were processed through StringTie v1.3.4. Gene counts were determined
- 428 with preDE.py (http://ccb.jhu.edu/software/stringtie/) based on results derived from Ballgown
- 429 (https://github.com/alyssafrazee/ballgown). Ensembl transcript annotation (version:
- 430 Homo_sapiens.GRCh38.93.gtf) with 58,395 genes was used.
- 431 A QC analysis and library filtering were performed before downstream biological
- 432 analysis. Libraries that passed the following criteria were retained: (i) more than five million
- reads; (ii) more than 90% of reads aligned to the human reference genome; (iii) over 10,000
- 434 genes were expressed (a gene with FPKM>0.5 was identified as an expressed gene). In
- 435 addition, to monitor data quality across batches, libraries of some heathy control samples

436	were constructed and	sequenced 2-3 times.	The average ex	pression p	profile of the multi	ple
						<u></u>

437 libraries from each heathy control sample were calculated for follow-up analyses.

438 *Immunoassay*

- 439 Immune repertoires were extracted with MiXCR, a software tool that extracts T-cell receptor
- 440 (TCR) and immunoglobulin (IG) repertoires from RNA-seq data (Bolotin et al., 2017; Bolotin et
- 441 al., 2015). The number of clonotypes was then calculated using VDJtools, using the output
- 442 from MiXCR (Shugay et al., 2015).

443 Differentially expressed genes (DEGs)

- 444 To identify DEGs, a Student's t-test was applied to the expression matrix. Genes with p-values
- less than 0.05 as well as a fold change >2 or <1/2 were labeled as up-regulated and
- 446 down-regulated genes, respectively (Su et al., 2014b). This straightforward approach of
- 447 combining a fold change cut-off with a non-stringent p-value threshold has been
- 448 demonstrated to yield reproducible and robust lists of DEGs for both microarray and RNA-seq
- 449 based gene-expression analyses (Shi et al., 2006; Su et al., 2014b).

450 *Functional and cell type enrichment analyses*

- 451 Functional analyses were conducted based on genes differentially expressed between
- 452 several subgroups of COVID-19 patients compared with healthy control samples. GSEA
- 453 (Gene Set Enrichment Analyses) was performed to identify significantly enriched functional
- 454 classes of gene sets correlated with blood transcription modules (BTM) described by Li et al.
- 455 (2014), KEGG pathways, and Gene Ontology (GO) terms. A default FDR (false discovery rate)

456	value of q \square < \square 0.25 was considered statistically significant. The Normalized Enrichment Score
457	(NES) of significant immune modules from BTMs was used to denote enrichment levels.
458	The fraction of the cell subsets was calculated using the enrichment-score based
459	algorithm xCell from the RNA-seq data (Aran et al., 2017). Briefly, the expression profile
460	(FPKM) of all 230 samples was employed as raw signatures. The R package immunedeconv
461	was applied to obtain enrichment scores of 35 immune cell types, estimating immune cell
462	fractions including T cell, monocyte and neutrophil by summation of the scores in each
463	sample (Sturm et al., 2019).
464	exRNA-seq data analysis
465	Alignment, quantification and quality control
466	Libraries were sequenced in two batches, with an average sequencing depth of 15.7M raw
467	reads per library. All FASTQ files were delivered to the ExceRpt small RNA sequencing data
468	analysis pipeline (docker v4.6.3) (Rozowsky et al., 2019). Default parameters were used with
469	exception of: (i) the sequence TGGAATTCTCGGGTGCCAAGG was given as the 3'adapter
470	sequence, ignoring the adapter sequences guessed by the pipeline; (ii) the random barcode
471	length was set to 4; (iii) the priority of the reference libraries during read assignment was set
472	to miRNA > piRNA > tRNA > GENCODE > circRNA (Godoy et al., 2018). Pre-compiled
473	genome and transcriptome indices of human genome, build 38 were used. The raw read
474	count matrix was then normalized using count per million (CPM).
475	A QC analysis was performed prior to biological analysis by removing (i) libraries with

- 476 low sequencing depths (<1M raw reads); (ii) libraries with mapping ratio lower than 50%, and
- 477 (iii) libraries with low transcript-genome ratios. To minimize the impact of noise due to low
- 478 expression levels, only 769 miRNAs with at least 1 count per million in no less than 10% of the
- total number of samples were included in the final analysis.

480 **Differentially expressed exRNAs**

- 481 To identify differentially expressed exRNAs, Student's t-tests were applied to the normalized
- 482 expression matrix. exRNAs with p-values less than 0.05, as well as fold change > 2 or < 1/2,
- 483 were labeled as up-regulated and down-regulated exRNAs, respectively, in a similar manner
- to the RNA-seq data.

485 Tissue-damage related miRNAs

- 486 exRNAs reported to be associated with tissue damage were collected from publications (Atif
- 487 and Hicks, 2019; Godwin et al., 2010; Wang et al., 2010; Wang et al., 2009; Zhou et al.,
- 488 2016)(Table S8). Fisher's exact test was used to determine whether the proportions of
- 489 differentially expressed (DE) exRNAs in tissue-damage related exRNAs were significantly
- 490 higher than the proportions of DE exRNAs in the entire data set of 769 miRNAs.
- 491 **Proteome analysis**

492 Plasma Protein extraction and trypsin digestion

- 493 Plasma samples used for protein extraction were first removed the tip 14 highest abundance
- 494 plasma proteins using an immunodepleting kit (Thermo Fisher) according to the
- 495 manufacturer's instructions, and then inactivated at 85°C for 10 mins. The depleted plasma

- 496 was digested by trypsin at an enzyme to protein mass ratio of 1:25 overnight at 37°C, and the
- 497 peptides were then extracted and dried (SpeedVac, Eppendorf).

498 LC-MS/MS Acquisition of Plasma Samples

- 499 Samples were measured using LC-MS instrumentation consisting of an EASY- nLC 1200
- 500 ultra-high-pressure system (Thermo Fisher Scientific) coupled via a nano-electrospray ion
- source (Thermo Fisher Scientific) to a Fusion Lumos Orbitrap (Thermo Fisher Scientific). The
- 502 peptides were dissolved with 12 µl loading buffer (0.1% formic acid in water), and 5 µl was
- 503 loaded onto a 100 μm l.D. × 2.5 cm, C18 trap column at a maximum pressure 280 bar with 14
- 504 μl solvent A (0.1% formic acid in water). Peptides were separated on 150 μm l.D. × 15 cm
- 505 column (C18, 1.9μm, 120 A ., Dr. Maisch GmbH) with a linear 15–30% Mobile Phase B (ACN
- and 0.1% formic acid) at 600 nl/min for 75 mins. The MS analysis was performed in a
- 507 data-independent manner. The DIA method consisted of MS1 scan from 300-1400 m/z at 60k
- resolution (AGC target 4e5 or 50 ms). Then 30 DIA segments were acquired at 15k resolution
- 509 with an AGC target 5e4 or 22 ms for maximal injection time. The setting "inject ions for all
- 510 available parallelizable time" was enabled. HCD fragmentation was set to normalized collision
- 511 energy of 30%. The spectra were recorded in profile mode. The default charge state for the
- 512 MS2 was set to 3.

513 **Peptide identification and protein quantification**

All data were processed using Firmiana (Feng et al., 2017). The DDA data were search

- against UniProt human protein database (updated on 2019.12.17, 20406 entries) using
- 516 FragPipe (v12.1) with MSFragger (2.2) (Kong et al., 2017). The mass tolerances were 20 ppm

517	for precursor and 50 mmu for product ions. Up to two missed cleavages were allowed. The
518	search engine set cysteine carbamidomethylation as a fixed modification and N-acetylation
519	and oxidation of methionine as variable modifications. Precursor ion score charges were
520	limited to +2, +3, and +4. The data were also searched against a decoy database so that
521	protein identifications were accepted at a false discovery rate (FDR) of 1%. The results of
522	DDA data were combined into spectra libraries using SpectraST software. A total of 327
523	libraries were used as reference spectra libraries.
524	DIA data was analyzed using DIANN (v1.7.0) (Demichev et al., 2020). The default
525	settings were used for DIA-NN (Precursor FDR: 5%, Log lev: 1, Mass accuracy: 20 ppm, MS1
526	accuracy: 10 ppm, Scan window: 30, Implicit protein group: genes, Quantification strategy:
527	robust LC (high accuracy). Quantification of identified peptides was calculated as the average
528	of chromatographic fragment ion peak areas across all reference spectra libraries. Label-free
529	protein quantifications were calculated using a label-free, intensity-based absolute
530	quantification (iBAQ) approach (Zhang et al., 2012). We calculated the peak area values as
531	parts of corresponding proteins. The fraction of total (FOT) was used to represent the
532	normalized abundance of a particular protein across samples. FOT was defined as a protein's
533	iBAQ divided by the total iBAQ of all identified proteins within a sample. The FOT values were
534	multiplied by 10^5 for the ease of presentation and missing values were imputed with 10^{-5} .

535 Metabolome analysis

536 NMR spectroscopy

The plasma samples used for NMR analysis were first treated with 56°C for 30 min. Our
subsequent quantitative measurements of samples from healthy controls showed that such
treatments caused no differences to the quantification results.

- 540 NMR analysis was conducted on a 600 MHz NMR spectrometer (Bruker Biospin) as
- 541 reported previously (Jimenez et al., 2018) with some minor modifications. In brief, 320µL of
- each plasma sample was mixed with 320µL of a phosphate buffer (0.085 M containing 10%
- 543 D₂O) with composition described previously (Jiang et al., 2012), and 600µL mixture was
- transferred into a 5mm NMR tube for NMR analysis. 152 parameters of the plasma were then
- 545 quantified using a server-based software package (Bruker Biospin), including 112 parameters
- 546 for lipoproteins (including main fractions, subclasses and compositional components therein),
- 547 two acute-phase glycoproteins together with 41 small metabolites (such as amino acids,
- 548 ketone bodies, glucose, carboxylic acids, ethanol). We also quantified six ratio-parameters for
- saturated, unsaturated, monounsaturated and polyunsaturated fatty acids from the
- diffusion-edited spectra (Xu et al., 2012). We further calculated 187 more ratio-parameters
- 551 (such as the cholesterol-to-triglyceride ratio, percentage of triglycerides and cholesterol in
- total lipids) from the quantitative data for lipoproteins. A total of 348 quantitative parameters
- 553 obtained were collectively employed to define the metabolomic phenotypes of each of the
- human plasma samples.

555 **Development of prognostic models**

556 *Model development*

557	Four data sets representing the (i) clinical tests, (ii) exRNA-seq, (iii) mRNA-seq, and (iv)
558	proteomics quantification analysis were used to develop prognostic models for the prediction
559	of patient outcomes (i.e. good or poor). Patients with a "good" outcome included those with
560	mild or severe syndrome but who were discharged after treatment; while patients with "poor"
561	outcomes included those who died or remained in ICU for more than two months.
562	Prognostic models were developed and validated using a two-layer validation strategy
563	(Fig. S5A) to prevent information leaking from the training set to the validation set ¹³ . Briefly,
564	patients were first divided into training and validation sets with equal size based on outcome
565	and admission date. The training set was then used to select variables and train prognostic
566	models using multiple machine learning algorithms, including nearest mean classification
567	(NMC), k-nearest neighbors (KNN), support vector machine (SVM), and random forest (RF)
568	through an internal-layer of 50 runs of five-fold cross-validation process to resist overfitting.
569	Next, a final model was built using the whole training set with the best performing machine
570	learning algorithm as defined above. The final model was further validated using the
571	validation set as an external-layer evaluation. Model performance was assessed in terms of
572	the Matthews correlation coefficient (MCC), AUC, accuracy, sensitivity, specificity, positive
573	predictive value (PPV) and negative predictive value (NPV).
574	Prognostic biomarkers were identified based on the frequency of variables selected by
575	machine learning algorithms. Because the sample size was relatively small compared to the
576	large number of variables, it was difficult to identify stable biomarkers as indicated by the low
577	frequencies of the variables used in the prognostic models ¹³ (Figs. S5A and S5B). To detect

- 578 more robust prognostic biomarkers, 50 runs of five-fold cross-validation process were
- 579 therefore applied to the whole data set. The variables used by the best performing machine
- 580 learning algorithm were identified as prognostic biomarkers for each data set.
- 581 Learning curve model comparison
- 582 Learning curve model comparison (LCMC) was performed using Predictive Modeling Review
- 583 as available in JMP Genomics 10
- 584 (https://www.jmp.com/en_us/software/genomics-data-analysis-software.html). LCMC reveals
- the effects of sample size on the accuracy and variability of the predictive models using 10
- 586 runs of 4-fold cross-validation.
- 587 We performed LCMC with prognosis (good or poor) as target variables, and the clinical
- variables, exRNA, mRNA, or proteomics measurements as predictors. Fig. S5C shows each
- 589 individual (RMSE) and (AUC) learning curve and the average for each of the eight partition
- 590 tree models for clinical endpoints, as well as exRNA using K-fold cross validation. The LCMC
- suggested that with up to 15 samples, eight partition tree models reached AUC as 1 for
- 592 clinical variables. However, more than 23 and 30 samples were needed for one and three
- 593 models, respectively, to reach AUC of 1 for exRNA-seq data. The variability of RMSE and
- 594 AUC for the proteomic and mRNA-seq data (not shown) were between that observed for
- 595 clinical variables and the exRNA data.

596 Statistical Analyses

597 Univariate statistical analysis was performed using student's t-test, Mann-Whitney U tests or

598 ANOVA tests to compare continuous variables. Chi-square tests and Fisher's exact tests

599	were used for the comparison of categorical variables. <i>p</i> -values were adjusted using
600	Bonferroni correction or the Benjamini and Hochbery False Discovery Rate (FDR) in multiple
601	comparisons, with $p < 0.05$ considered to be statistically significant. Principal components
602	analysis (PCA) was conducted with univariance scaling, with the scores plot showing a
603	distribution of metabolomic phenotypes for healthy participants and patients with moderate or
604	severe COVID-19 (and upon discharge). Correlations were tested using Pearson correlation
605	coefficients. Locally Weighted Linear Regression (Loess) was used for visualizing the time
606	series data. All analyses were performed using appropriate R packages (version 3.5.1).
607	
608	Acknowledgements
609	We acknowledge the support from Volvo Car Corporation. This study was supported by the
610	National Natural Science Foundation of China (grants 81861138003, 31930001, 32041004
611	
	and 81672057) and the Special National Project on investigation of basic resources of China
612	and 81672057) and the Special National Project on investigation of basic resources of China (grant 2019FY101400), and Shanghai Municipal Science and Technology Major Project
612 613	and 81672057) and the Special National Project on investigation of basic resources of China (grant 2019FY101400), and Shanghai Municipal Science and Technology Major Project (Grant No. 2017SHZDZX01). E.C.H. is supported by an ARC Australian Laureate Fellowship
612 613 614	and 81672057) and the Special National Project on investigation of basic resources of China (grant 2019FY101400), and Shanghai Municipal Science and Technology Major Project (Grant No. 2017SHZDZX01). E.C.H. is supported by an ARC Australian Laureate Fellowship (FL170100022).
612 613 614 615	and 81672057) and the Special National Project on investigation of basic resources of China (grant 2019FY101400), and Shanghai Municipal Science and Technology Major Project (Grant No. 2017SHZDZX01). E.C.H. is supported by an ARC Australian Laureate Fellowship (FL170100022).
612 613 614 615 616	and 81672057) and the Special National Project on investigation of basic resources of China (grant 2019FY101400), and Shanghai Municipal Science and Technology Major Project (Grant No. 2017SHZDZX01). E.C.H. is supported by an ARC Australian Laureate Fellowship (FL170100022).

and L.J. designed and developed methodology. T.-Y.Z., Y.L. and Z.-G.S. performed the

619 clinical work and sample collection. Y.-M.C, Y.-T.Z., Y.-Z.W., Q.-X.H., S.-Y.S., Z.-G.S.,

- 620 F.-H.D., Y.-P.A., Q.-S.C. and Q.-W. L. performed the experiments. Y.Y., Y.-Z.W., Q.-X.H.,
- 621 Y.-M.C., F.Q, L.S., Z.-Y.C., J.-C.Y., Z.-Q.S., J.-W.F. and P.-C.L. analysed the data. Y.-Z.Z.,
- 622 C.D., F.Q, L.S., Y.Y., Y.-Z.W., Y.-M.C., Q.-X.H., L.M.S., H.R.T. and E.C.H. wrote the paper
- 623 with input from all authors.
- 624
- 625 Conflict of interest
- 626 The authors declare no competing interests.
- 627

628 Data Availability

- 629 The datasets produced in this study are available in the following databases:
- 630 RNA-Seq and exRNA-Seq Data: NODE **OEP000868**
- 631 (http://www.biosino.org/node/project/detail/OEP000868)
- Raw mass spectrometry data: iProX IPX 0002186001
- 633 (https://www.iprox.org/page/subproject.html?id=IPX0002186001)

635 References

- 636 Akiyama, M., Zeisbrich, M., Ibrahim, N., Ohtsuki, S., Berry, G.J., Hwang, P.H., et al. (2019).
- 637 Neutrophil extracellular traps induce tissue-invasive monocytes in granulomatosis with
- 638 polyangiitis. Front Immunol 13 Noverber DOI: 103389/fimmu201902617.
- Alonso, D.O., Iglesias, A., Coelho, R., Periolo, N., Bruno, A., Córdoba, M.T., et al. (2019).
- 640 Epidemiological description, case-fatality rate, and trends of Hantavirus Pulmonary
- 641 Syndrome: 9 years of surveillance in Argentina. J Med Virol 91: 1173-1181.
- Aran, D., Hu, Z., and Butte, A.J. (2017). xCell: digitally portraying the tissue cellular
- heterogeneity landscape. Genome Biol 18: 220.
- Atif, H., and Hicks, S.D. (2019). A Review of MicroRNA Biomarkers in Traumatic Brain Injury.
- 645 J Exp Neurosci 13: 1179069519832286.
- 646 Baig, A.M. (2020). Neurological manifestations in COVID-19 caused by SARS-CoV-2. CNS
- 647 Neurosci Ther 26: 499.
- Baig, A.M., Khaleeq, A., Ali, U., and Syeda, H. (2020). Evidence of the COVID-19 Virus
- 649 Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed
- 650 Neurotropic Mechanisms. ACS Chem Neurosci 11: 995-998.
- Barton, L.M., Duval, E.J., Stroberg, E., Ghosh, S., and Mukhopadhyay, S. (2020). COVID-19
- 652 Autopsies, Oklahoma, USA. Am J Clin Pathol, 10 April, DOI:
- 653 https://doiorg/101093/ajcp/agaa062.
- Baseler, L., Chertow, D.S., Johnson, K.M., Feldmann, H., and Morens, D.M. (2017). The
- 655 pathogenesis of Ebola virus disease. Annu Rev Pathol 12: 387-418.

656	Bermingham, A., Chand, M., Brown, C., Aarons, E., Tong, C., Langrish, C., et al. (2012).
657	Severe respiratory illness caused by a novel coronavirus, in a patient transferred to
658	the United Kingdom from the Middle East, September 2012. Euro Surveill 17: 20290.
659	Blanco-Melo, D., Nilsson-Payant, B.E., Liu, WC., Uhl, S., Hoagland, D., Møller, R., et al.
660	(2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19.
661	Cell, DOI: 101016/jcell202004026.
662	Bohmwald, K., Gálvez, N.M., Canedo-Marroquín, G., Pizarro-Ortega, M.S., Andrade-Parra,
663	C., Gómez-Santander, F., and Kalergis, A.M. (2019). Contribution of cytokines to
664	tissue damage during human respiratory syncytial virus infection. Front Immunol 18
665	March DOI: 103389/fimmu201900452.
666	Bolotin, D.A., Poslavsky, S., Davydov, A.N., Frenkel, F.E., Fanchi, L., Zolotareva, O.I., et al.
667	(2017). Antigen receptor repertoire profiling from RNA-seq data. Nat Biotechnol 35:
668	908-911.
669	Bolotin, D.A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I.Z., Putintseva, E.V.,
670	and Chudakov, D.M. (2015). MiXCR: software for comprehensive adaptive immunity
671	profiling. Nat Methods 12: 380-381.
672	Cai, Q., Huang, D., Yu, H., Zhu, Z., Xia, Z., Su, Y., et al. (2020). Characteristics of Liver Tests
673	in COVID-19 Patients. J Hepatol 13 April DOI: https://doiorg/101016/jjhep202004006.
674	Cao, X. (2020). COVID-19: immunopathology and its implications for therapy. Nat Rev
675	Immunol 09 April DOI: https://doiorg/101038/s41577-020-0308-3.

- 676 Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., et al. (2020). Specific ACE2 expression in
- 677 cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv DOI:
- 678 <u>https://doiorg/101101/20200203931766</u>.
- 679 Channappanavar, R., Zhao, J., and Perlman, S. (2014). T cell-mediated immune response to
- 680 respiratory coronaviruses. Immunol Res 59: 118-128.
- 681 Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020a). Epidemiological and
- 682 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
- 683 China: a descriptive study. The Lancet 30 January DOI:
- 684 <u>https://doiorg/101016/S0140-6736(20)30211-7</u>.
- 685 Chen, R., Yu, J., Wang, K., Chen, Z., Wen, C., and Xu, Z. (2020b). The spatial and cell-type
- 686 distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. bioRxiv DOI:

687 <u>https://doiorg/101101/20200407030650</u>.

- 688 Chen, S., Zhou, Y., Chen, Y., and Gu, J. (2018). fastp: an ultra-fast all-in-one FASTQ
- 689 preprocessor. Bioinformatics 34: i884-i890.
- 690 Cheng, Y., Ma, X.L., Wei, Y.Q., and Wei, X.W. (2019). Potential roles and targeted therapy of
- the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta
 Rev Cancer 1871: 289-312.
- 693 Chung, K.F. (2011). p38 mitogen-activated protein kinase pathways in asthma and COPD.
- 694 Chest 139: 1470-1479.

- 695 Cicchese, J.M., Evans, S., Hult, C., Joslyn, L.R., Wessler, T., Millar, J.A., et al. (2018).
- 696 Dynamic balance of pro-and anti-inflammatory signals controls disease and limits
- 697 pathology. Immunol Rev 285: 147-167.
- 698 Cui, J., Li, F., and Shi, Z.-L. (2019). Origin and evolution of pathogenic coronaviruses. Nat
- 699 Rev Microbiol 17: 181-192.
- Dada, L.A., Chandel, N.S., Ridge, K.M., Pedemonte, C., Bertorello, A.M., and Sznajder, J.I.
- 701 (2003). Hypoxia-induced endocytosis of Na, K-ATPase in alveolar epithelial cells is
- mediated by mitochondrial reactive oxygen species and PKC-ζ. J Clin Invest 111:
- 703 1057-1064.
- Demichev, V., Messner, C.B., Vernardis, S.I., Lilley, K.S., and Ralser, M. (2020). DIA-NN:
- 705 neural networks and interference correction enable deep proteome coverage in high
- throughput. Nat Methods 17: 41-44.
- 707 Du, X., Yu, X., Li, Q., Li, X., Qin, T., Luo, Q., et al. (2020). Duration for Carrying SARS-CoV-2
- in COVID-19 Patients. J Infect Dis.
- Fan, C., Li, K., Ding, Y., Lu, W.L., and Wang, J. (2020). ACE2 expression in kidney and testis
- 710 may cause kidney and testis damage after 2019-nCoV infection. MedRxiv DOI:
- 711 <u>https://doiorg/101101/2020021220022418</u>.
- Feng, J., Ding, C., Qiu, N., Ni, X., Zhan, D., Liu, W., et al. (2017). Firmiana: towards a
- one-stop proteomic cloud platform for data processing and analysis. Nat Biotechnol 35:
- 714 409-412.

715	Gautam, N., Olofsson, A.M., Herwald, H., Iversen, L.F., Lundgren-Åkerlund, E., Hedqvist, P.,
716	et al. (2001). Heparin-binding protein (HBP/CAP37): a missing link in
717	neutrophil-evoked alteration of vascular permeability. Nat Med 7: 1123-1127.
718	Godoy, P.M., Bhakta, N.R., Barczak, A.J., Cakmak, H., Fisher, S., MacKenzie, T.C., et al.
719	(2018). Large Differences in Small RNA Composition Between Human Biofluids. Cell
720	Rep 25: 1346-1358.
721	Godwin, J.G., Ge, X., Stephan, K., Jurisch, A., Tullius, S.G., and Iacomini, J. (2010).
722	Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl
723	Acad Sci U S A 107: 14339-14344.
724	Guan, Wj., Ni, Zy., Hu, Y., Liang, Wh., Ou, Cq., He, Jx., et al. (2020). Clinical
725	characteristics of coronavirus disease 2019 in China. N Engl J Med 28 February DOI:
726	101056/NEJMoa2002032.
727	Halayko, A.J., and Ghavami, S. (2009). S100A8/A9: a mediator of severe asthma
728	pathogenesis and morbidity? Can J Physiol Pharmacol 87: 743-755.
729	Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., and van Goor, H. (2004). Tissue
730	distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step
731	in understanding SARS pathogenesis. J Pathol 203: 631-637.
732	Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of
733	patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395:
734	497-506.

735	Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., et al. (2014).
736	Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat
737	Rev Cardiol 11: 413-426.
738	Jiang, L., Huang, J., Wang, Y., and Tang, H. (2012). Eliminating the dication-induced
739	intersample chemical-shift variations for NMR-based biofluid metabonomic analysis.
740	Analyst 137: 4209-4219.
741	Jimenez, B., Holmes, E., Heude, C., Tolson, R.F., Harvey, N., Lodge, S.L., et al. (2018).
742	Quantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in
743	Human Serum and Plasma by (1)H NMR Spectroscopy in a Multilaboratory Trial. Anal
744	Chem 90: 11962-11971.
745	Kong, A.T., Leprevost, F.V., Avtonomov, D.M., Mellacheruvu, D., and Nesvizhskii, A.I. (2017).
746	MSFragger: ultrafast and comprehensive peptide identification in mass
747	spectrometry-based proteomics. Nat Methods 14: 513.
748	Kruger, P., Saffarzadeh, M., Weber, A.N., Rieber, N., Radsak, M., von Bernuth, H., et al.
749	(2015). Neutrophils: between host defence, immune modulation, and tissue injury.
750	PLoS Pathog 11: e1004651.
751	Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., Emery, S., et al. (2003). A
752	novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med
753	348: 1953-1966.

754	Li, S., Rouphael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., et al.
755	(2014). Molecular signatures of antibody responses derived from a systems biology
756	study of five human vaccines. Nat Immunol 15: 195-204.
757	Lin, L., Lu, L., Cao, W., and Li, T. (2020). Hypothesis for potential pathogenesis of
758	SARS-CoV-2 infection——a review of immune changes in patients with viral
759	pneumonia. Emerg Microbes Infect: 1-14.
760	Mao, L., Wang, M., Chen, S., He, Q., Chang, J., Hong, C. <i>, et al.</i> (2020). Neurologic
761	Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan,
762	China. JAMA Neurol 10 April DOI: 101001/jamaneurol20201127.
763	Masters, P., and Perlman, S. (2013). "Coronaviridae", Fields virology, Vol 1 (Lippincott
764	Williams & Wilkins, Philadelphia, PA).
765	Mattos, W., Lim, S., Russell, R., Jatakanon, A., Chung, K.F., and Barnes, P.J. (2002). Matrix
766	Metalloproteinase-9 Expression in Asthma: Effect of Asthma Severity, Allergen
767	Challenge, and Inhaled Corticosteroids. Chest 122: 1543-1552.
768	Murphy, K., and Weaver, C. (2016). Janeway's immunobiology 9th edition (Garland Science).
769	Newton, A.H., Cardani, A., and Braciale, T.J. (2016). The host immune response in
770	respiratory virus infection: balancing virus clearance and immunopathology. Semin
771	Immunopathol 38: 471-482.
772	Oschatz, C., Maas, C., Lecher, B., Jansen, T., Björkqvist, J., Tradler, T. <i>, et al.</i> (2011). Mast
773	cells increase vascular permeability by heparin-initiated bradykinin formation in vivo.
774	Immunity 34: 258-268.

775	Pertea, M., Kim, D., Pertea, G.M., Leek, J.T., and Salzberg, S.L. (2016). Transcript-level
776	expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat
777	Protoc 11: 1650-1667.
778	Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., et al. (2020). Dysregulation of immune
779	response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 12 Mar DOI:
780	101093/cid/ciaa248.
781	Rozowsky, J., Kitchen, R.R., Park, J.J., Galeev, T.R., Diao, J., Warrell, J., et al. (2019).
782	exceRpt: A Comprehensive Analytic Platform for Extracellular RNA Profiling. Cell Syst
783	8: 352-357.e353.
784	Ruibal, P., Oestereich, L., Ludtke, A., Becker-Ziaja, B., Wozniak, D.M., Kerber, R., et al.
785	(2016). Unique human immune signature of Ebola virus disease in Guinea. Nature
786	533: 100-104.
787	Shi, L., Campbell, G., Jones, W.D., Campagne, F., Wen, Z., Walker, S.J., et al. (2010). The
788	MicroArray Quality Control (MAQC)-II study of common practices for the development
789	and validation of microarray-based predictive models. Nat Biotech 28: 827.
790	Shi, L., Reid, L.H., Jones, W.D., Shippy, R., Warrington, J.A., Baker, S.C., et al. (2006). The
791	MicroArray Quality Control (MAQC) project shows inter- and intraplatform
792	reproducibility of gene expression measurements. Nat Biotechnol 24: 1151-1161.
793	Shi, Y., Tan, M., Chen, X., Liu, Y., Huang, J., Ou, J., and Deng, X. (2020).
794	Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou,
795	China. medRxiv DOI: 101101/2020031220034736: 2020.2003.2012.20034736.

796	Shugay, M.,	Bagaev, D	.V	Turchaninova.	M.A.	Bolotin.	. D.A.	Britanova	. O.V.	Putintseva.
			,							

- 797 E.V., et al. (2015). VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires.
- 798 PLoS Comput Biol 11: e1004503.
- 799 Sparano, J.A., Gray, R.J., Makower, D.F., Pritchard, K.I., Albain, K.S., Hayes, D.F., et al.
- 800 (2018). Adjuvant chemotherapy guided by a 21-gene expression assay in breast
- 801 cancer. N Engl J Med 379: 111-121.
- 802 Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., et al.
- 803 (2013). Cellular immune correlates of protection against symptomatic pandemic
- influenza. Nat Med 19: 1305-1312.
- 805 Sturm, G., Finotello, F., Petitprez, F., Zhang, J.D., Baumbach, J., Fridman, W.H., et al. (2019).
- 806 Comprehensive evaluation of transcriptome-based cell-type quantification methods for

immuno-oncology. Bioinformatics 35: i436-i445.

- 808 Su, Z., Fang, H., Hong, H., Shi, L., Zhang, W., Zhang, W., et al. (2014a). An investigation of
- biomarkers derived from legacy microarray data for their utility in the RNA-seq era.
- 810 Genome Biol 15: 523.
- 811 Su, Z., Łabaj, P.P., Li, S., Thierry-Mieg, J., Thierry-Mieg, D., Shi, W., et al. (2014b). A
- 812 comprehensive assessment of RNA-seq accuracy, reproducibility and information
- content by the Sequencing Quality Control Consortium. Nat Biotechnol 32: 903-914.
- Tian, S., Hu, W., Niu, L., Liu, H., Xu, H., and Xiao, S.-Y. (2020). Pulmonary pathology of early
- 815 phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung
- 816 cancer. J Thorac Oncol 27 February DOI: <u>https://doiorg/101016/jjtho202002010</u>.

817	Vadász, I., and Sznajder, J.I. (2017). Gas exchange disturbances regulate alveolar fluid
818	clearance during acute lung injury. Front Immunol 8: 757.
819	van de Sandt, C.E., Kreijtz, J.H., de Mutsert, G., Geelhoed-Mieras, M.M., Hillaire, M.L.,
820	Vogelzang-van Trierum, S.E., et al. (2014). Human cytotoxic T lymphocytes directed
821	to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J
822	Virol 88: 1684-1693.
823	Wadman, M., Couzin-Frankel, J., Kaiser, J., and Matacic, C. (2020). How does coronavirus
824	kill? Clinicians trace a ferocious rampage through the body, from brain to toes.
825	Science 17 April
826	https://wwwsciencemagorg/news/2020/04/how-does-coronavirus-kill-clinicians-trace-f
827	erocious-rampage-through-body-brain-toes.
828	Wang, B., Wang, L., Kong, X., Geng, J., Xiao, D., Ma, C. <i>, et al.</i> (2020a). Long-term
829	coexistence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
830	with antibody response in Coronavirus Disease 2019 (COVID-19) Patients. medRxiv
831	DOI: https://doiorg/101101/2020041320040980.
832	Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020b). Clinical characteristics of
833	138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,
834	China. JAMA 323: 1061-1069.
835	Wang, G.K., Zhu, J.Q., Zhang, J.T., Li, Q., Li, Y., He, J., et al. (2010). Circulating microRNA: a
836	novel potential biomarker for early diagnosis of acute myocardial infarction in humans.
837	Eur Heart J 31: 659-666.

838	Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., et al. (2009). Circulating
839	microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S
840	A 106: 4402-4407.
841	Wang, X., Fang, X., Cai, Z., Wu, X., Gao, X., Min, J., and Wang, F. (2020c). Comorbid
842	Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease
843	Severity and Mortality among COVID-19 Patients: A Systemic Review and
844	Meta-Analysis. Research 2020: 2402961.
845	Wang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z. <i>, et al</i> . (2020d). SARS-CoV-2 infects T
846	lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol 7
847	April DOI: 101038/s41423-020-0424-9: 1-3.
848	Wang, Z., Wan, Y., Qiu, C., Quinones-Parra, S., Zhu, Z., Loh, L., et al. (2015). Recovery from
849	severe H7N9 disease is associated with diverse response mechanisms dominated by
850	CD8(+) T cells. Nat Commun 6: 6833.
851	WHO (2020). Coronavirus disease 2019 (COVID-19) Situation Report – 131.
852	Wu, F., Zhao, S., Yu, B., Chen, YM., Wang, W., Song, ZG., et al. (2020a). A new
853	coronavirus associated with human respiratory disease in China. Nature 579:
854	265-269.
855	Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., et al. (2020b). Nervous system
856	involvement after infection with COVID-19 and other coronaviruses. Brain Behav
857	Immun.

- 858 Wynants, L., Van Calster, B., Bonten, M.M., Collins, G.S., Debray, T.P., De Vos, M., et al.
- 859 (2020). Prediction models for diagnosis and prognosis of covid-19 infection:
- systematic review and critical appraisal. BMJ 369: m1328.
- Xiang, P., Xu, X., Gao, L., Wang, H., Xiong, H., and Li, R. (2020). First case of 2019 novel
- coronavirus disease with Encephalitis. ChinaXiv 202003: 00015.
- Xu, W., Wu, J., An, Y., Xiao, C., Hao, F., Liu, H., et al. (2012). Streptozotocin-induced
- dynamic metabonomic changes in rat biofluids. J Proteome Res 11: 3423-3435.
- Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al. (2020). Pathological findings
- of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med
 867 8: 420-422.
- 868 Zhang, W., Yu, Y., Hertwig, F., Thierry-Mieg, J., Zhang, W., Thierry-Mieg, D., et al. (2015).
- 869 Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.
- 870 Genome Biol 16: 133.
- Zhang, W., Zhang, J., Xu, C., Li, N., Liu, H., Ma, J., et al. (2012). LFQ uant: A label-free fast
- quantitative analysis tool for high-resolution LC-MS/MS proteomics data. Proteomics
 12: 3475-3484.
- 874 Zhao, J., Zhao, J., and Perlman, S. (2010). T cell responses are required for protection from
- 875 clinical disease and for virus clearance in severe acute respiratory syndrome
- 876 coronavirus-infected mice. J Virol 84: 9318-9325.
- Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., and Xie, X. (2020). COVID-19 and the cardiovascular
- 878 system. Nat Rev Cardiol 17: 259-260.

	879 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et	et al. (2020a). Clinical course and risk fact
--	---	---

- for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
- study. The Lancet 395: 1054-1062.
- 882 Zhou, M., Hara, H., Dai, Y., Mou, L., Cooper, D.K., Wu, C., and Cai, Z. (2016). Circulating
- 883 Organ-Specific MicroRNAs Serve as Biomarkers in Organ-Specific Diseases:
- 884 Implications for Organ Allo- and Xeno-Transplantation. Int J Mol Sci 17.
- 885 Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., et al. (2020b). A pneumonia
- outbreak associated with a new coronavirus of probable bat origin. Nature 579:
- 887 270-273.
- Zhou, Y., Fu, B., Zheng, X., Wang, D., and Zhao, C. (2020c). Pathogenic T cells and
- 889 inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl

890 Sci Rev 13 March DOI: 101093/nsr/nwaa041.

- Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A novel coronavirus
- from patients with pneumonia in China, 2019. N Engl J Med.
- Zou, X., Chen, K., Zou, J., Han, P., Hao, J., and Han, Z. (2020). Single-cell RNA-seq data
- analysis on the receptor ACE2 expression reveals the potential risk of different human
- organs vulnerable to 2019-nCoV infection. Front Med: 1-8.

897 Figure Legends

898 Fig. 1 Study design and patient cohort.

- (A) Schematic summary of the study design and patient cohort. Total sample numbers before
- 900 quality control are shown for each omics data set.
- 901 (B) The number of expressed genes and detected proteins, metabolites, exRNAs and clinical
- 902 parameters in high quality patient samples.
- 903 (C) Summary of differentially expressed genes, proteins, metabolites and exRNAs between
- 904 uninfected controls and COVID-19 patients (mild and severe) in the multi-omics data.

905

906 Fig. 2 Molecular characteristics of COVID-19 patients.

- 907 (A) Scores of principal components 1(PC1) of each sample from the transcriptome, proteome,
- 908 metabolome, and exRNA-seq principal component analyses.
- 909 (B) Circos plots showing the significant correlations between clinical parameters and the
- 910 multi-omics data.
- 911 (C) The cluster heatmap represents expression patterns in the 1,656, 1,547 and 2,362
- 912 proteins that showed significant upregulation (fold change>2) in the control, mild and severe
- 913 patient groups. The top categories enriched for clusters are shown. Values for each protein in
- all analyzed regions (columns) are color-coded based on expression level, low (blue) and
- 915 high (red) z-scored FOT.
- 916 (D) The WGCNA of COVID-19 samples shows modules that are highly correlated with clinical
- 917 features (left heatmap). Enrichment analysis for different modules is presented in the right

918 heatmap (*p* value <0.05).

- 919 (E) Boxplot indicates the APTT time between mild and severe COVID-19 patients. The
- 920 heatmap indicates the module 1 enriched protein expression patterns among mild and severe
- 921 patients.
- 922 (F) Boxplot indicates the IL-6 and IL-10 levels among mild and severe COVID-19 patients.
- 923 The heatmap indicates the module 2 enriched protein expression patterns among mild and
- 924 severe patients. Differences between groups were estimated using ANOVA. For all boxplots,
- the horizontal box lines in the boxplots represent the first quartile, the median, and the third
- 926 quartile. Whiskers denote the range of points within the first quartile 1.5× the interquartile
- 927 range and the third quartile + 1.5× the interquartile range.
- 928
- 929 Fig. 3 Patterns of tissue damage associated with COVID-19.
- 930 (A) The distribution of tissue-enhanced proteins across the major tissues affected by
- 931 COVID-19. Proteins whose expression altered in COVID-19 patients are colored red.
- 932 (B) Heatmap indicating expression patterns of known tissue specific biomarkers among
- 933 control, mild and severe patient groups.
- 934 (C) Systematic summary of brain-enhanced expressed proteins and signaling cascades
- significantly altered in COVID-19 patients (neurotransmitters transport, synthesis). Values for
- each protein at all analyzed samples (columns) are color-coded based on the expression
- 937 level, low (green) and high (red) z-scored FOT.
- 938 (D) Network summarizing lung-enhanced expressed proteins and signaling cascades

- significantly altered in COVID-19 patients (HIF-1α signaling pathway).
- 940 (E) Network summarizing liver-enhanced expressed proteins and signaling cascades
- significantly altered in COVID-19 patients (Lipid metabolism).
- 942 (F) Boxplot indicating the expression level of known brain dysfunctional biomarkers in control,
- 943 mild and severe patients.
- 944 (G) Heatmap showing normalized x-cell scores of specific cell types across control, mild and
- severe COVID-19 patients. *p < 0.05 (t test).
- 946 (H) Heatmap showing the expression of cell type specific signatures among control, mild and
- 947 severe COVID-19 patients.
- 948 (I) Systematic summary of the GO pathways enriched by tissue-enhanced proteins that
- 949 exhibited altered expression among control, mild, and severe patient groups. The heatmap of
- 950 each panel indicates expression patterns of tissues-enhanced proteins among control, mild,
- and severe patient groups. The fold changes in tissue-enhanced proteins between
- mild/severe patient samples and control samples are shown on the right of heatmap.

953

954 Fig. 4 Differences in immune responses among COVID-19 patients.

- 955 (A) Transcriptional profiles reflect the dynamic immune response in COVID-19. GSEA (FDR
- 956 < 0.25; 1,000 permutations) was used to identify positive (red), negative (blue) or no (white)</p>
- 957 enrichment of BTMs (gene sets). The graph shows the normalized enrichment score (NES) of
- 958 each selected BTM in the different time points (T1, T2 and T3) for patients with mild or severe
- 959 COVID-19 illness, in comparison to healthy controls.

- 960 (B) Expression levels of NETs' markers for individual transcripts in severe versus mild
- comparisons. Data are represented as means \pm SEM, *p < 0.05; ***p < 0.001 (t test).
- 962 (C) Heatmap of *IFNG*, *GZMB* and *PRF1* gene expression in COVID-19 patients.
- 963 (D) Heatmap of genes enriched in IL-17 signaling pathway between healthy control and
- 964 COVID-19 patients.
- 965 (E) T cell and innate immune response elucidate immunopathology of COVID-19.
- 966

967 Fig. 5 COVID-19-associated metabolomic changes in blood plasma.

- 968 (A) Plasma metabolomic changes revealed a trajectory in COVID-19 severity, from healthy
- 969 control, mild, to severe.
- 970 (B) Changes in the concentration of plasma metabolites are associated with COVID-19
- 971 severity. The discharge group consist of all patients (mild and severe) that were recovered
- 972 and discharged.
- 973 (C) COVID-19 severity is associated with significant changes in lipoprotein subclasses
- 974 including high-density lipoprotein subclass-1 (HDL1), HDL4, low-density lipoprotein
- 975 subclasses (LDL1, LDL4, LDL5), very low-density lipoprotein subclass-5 (VLDL5) and their
- 976 compositional components (ApoA1, triglycerides, cholesterol).
- 977 (D) Plasma levels of key enzymes and proteins directly involving lipoprotein metabolism are
- 978 indicators for COVID-19 severity. *p < 0.05; **p < 0.01; ***p < 0.001 (t test). sLDLR: soluble
- 979 low density lipoprotein receptor; LCAT: lecithin-cholesterol acyltransferase; CEPT:
- 980 cholesteryl-ester transfer protein.

981 ((E)	COVID-19 caused d	ysregulation in li	poprotein metabolism,	glycol	lysis and TC	A cycle. T	ſhe
			1	,		1	-	

- 982 three boxes from left to right are control, mild and severe, in which gray means normal, blue
- means decrease, red means increase. H1: HDL1; H3: HDL3; H4: HDL4; L1: LDL1, L3: LDL3;
- 984 L4: LDL4; L5: LDL5; V1: VLDL1; V4: VLDL4; V5: VLDL5; TG: triglycerides; FC: free
- 985 cholesterol; CE: cholesteryl esters; CH: total cholesterol (i.e., FC + CE); PL: total
- 986 phospholipids; H4A1, H4A2: ApoA1 and ApoA2 in HDL4; H-A1, H-A2: ApoA1, ApoA2 (in both
- HDL and nascent HDL); L1TG: TG in LDL1; L1%: LDL1 percentage in all LDL; TG%, FC%,
- 988 CE%: percentages of TG, FC and CE, respectively, in total lipids of given lipoprotein
- 989 subclasses; L-TG/L-CH: TG-to-CH ratio in LDL; H4CH/H4TG: CH-to-TG ratio in HDL4;
- 990 V1CH/V1TG: CH-to-TG ratio in VLDL1. CS: Citrate synthase; IDH: Isocitrate dehydrogenase;
- 991 ACO2: Aconitase; OGDH: α-ketoglutarate dehydrogenase; DLD: Dihydrolipoyl
- 992 dehydrogenase; SDH: Succinic dehydrogenase; MDH: Malate dehydrogenase; PDH:
- 993 Pyruvate dehydrogenase; PDK: Pyruvate dehydrogenase kinase; ACLY: ATP citrate lyase;
- 994 ACAC: Acetyl coenzyme A carboxylase; FASN: Fatty acid synthetase; LDH: Lactate

995 dehydrogenase.

996

997 Fig. 6 Comparative analysis of severe-survival patients and severe-fatal patients

998 (A) Bar plot comparison of viral loads between severe-survival patients and severe-fatal

- patients. The cluster heatmap represents expression patterns of 1,541 proteins that exhibited
- 1000 temporal changes across time points in severe-survival patients. Line graph represents the
- 1001 temporal changes in viral load in time (days) after hospital admission of the patients.

1002 (B) Enriched annotations for corresponding clusters showed in Fig. 6A.

- 1003 (C-D) Systematic summary of proteins and signaling cascades significantly altered in
- severe-survival patients (lipid metabolism; c) and severe-fatal (viral life cycle; d). Values for
- 1005 each protein in all samples analyzed (columns) are color-coded based on the expression level,
- 1006 low (blue) and high (red) z-scored FOT.
- 1007 (E) For each of the four panels, the heatmaps on the left indicated the Pearson correlation of
- 1008 proteins with viral load in severe survivors and severe fatalities, the heatmap on the right
- 1009 indicated the significant pathways enriched by proteins positively or negatively correlated with
- 1010 viral load in severe survivors and severe fatalities.
- 1011
- 1012 Fig. 7 Biomarkers predictive of clinical outcomes of COVID-19 patients.
- 1013 (A) Principal component analysis of exRNA, transcriptome, proteome, and clinical covariate
- 1014 data from samples collected at the first timepoint. The first two components were used to
- 1015 describe the distribution of samples based on expressed genes, proteins and clinical data,
- 1016 respectively, whereas the first and third components were used for samples based on the
- 1017 exRNA data.
- 1018 (B) Performance of prognostic models based on exRNA, transcriptome, proteome, and the
- 1019 corresponding clinical covariate data sets. Model performance of the five-fold cross-validation
- 1020 was assessed using the Matthews correlation coefficient (MCC), AUC, accuracy, sensitivity,
- 1021 specificity, positive predictive value (PPV) and negative predictive value (NPV).
- 1022 (C) The most frequently selected features of exRNA-, transcriptome-, proteome-, and

1023 clinical-based models. Features were simultaneously identified fro	m each of the four data se	ts
---	----------------------------	----

- and for each of the four machine learning algorithms based on the frequency of variables
- 1025 used by AI models during 50 runs of the five-fold cross-validation.
- 1026 (D) Correlation heatmap among the most frequently selected features (frequency > 0.78)
- 1027 used in the exRNA-based model. Members in the let-7 family selected for the exRNA-based
- 1028 predictors (hsa-miR-98-5p, hsa-let-7a-5p, hsa-let-7d-5p, hsa-let-7f-5p) were highly correlated
- 1029 with each other.
- 1030 (E-I) Biomarkers identified from exRNA (E), transcriptome (F), proteome (H) and clinical data
- 1031 (I) based models exhibited a clear separation between those patients with either good or poor
- 1032 prognosis. (G) Functional enrichment of 110 protein features selected from random forest
- 1033 modeling.



1

2

Fig. 1 Study design and patient cohort.

3 (A) Schematic summary of the study design and patient cohort. Total sample numbers

- 4 before quality control are shown for each omics data set.
- 5 (B) The number of expressed genes and detected proteins, metabolites, exRNAs and
- 6 clinical parameters in high quality patient samples.

- 7 (C) Summary of differentially expressed genes, proteins, metabolites and exRNAs between
- 8 uninfected controls and COVID-19 patients (mild and severe) in the multi-omics data.



10

11 Fig. 2 Molecular characteristics of COVID-19 patients.

- 12 (A) Scores of principal components 1(PC1) of each sample from the transcriptome,
- 13 proteome, metabolome, and exRNA-seq principal component analyses.
- 14 (B) Circos plots showing the significant correlations between clinical parameters and the
- 15 multi-omics data.
- 16 (C) The cluster heatmap represents expression patterns in the 1,656, 1,547 and 2,362
- 17 proteins that showed significant upregulation (fold change>2) in the control, mild and severe
- 18 patient groups. The top categories enriched for clusters are shown. Values for each protein
- 19 in all analyzed regions (columns) are color-coded based on expression level, low (blue) and
- 20 high (red) z-scored FOT.
- 21 (D) The WGCNA of COVID-19 samples shows modules that are highly correlated with
- 22 clinical features (left heatmap). Enrichment analysis for different modules is presented in the

right heatmap (*p* value <0.05).

- 24 (E) Boxplot indicates the APTT time between mild and severe COVID-19 patients. The
- 25 heatmap indicates the module 1 enriched protein expression patterns among mild and

severe patients.

- 27 (F) Boxplot indicates the IL-6 and IL-10 levels among mild and severe COVID-19 patients.
- 28 The heatmap indicates the module 2 enriched protein expression patterns among mild and
- 29 severe patients. Differences between groups were estimated using ANOVA. For all boxplots,
- 30 the horizontal box lines in the boxplots represent the first quartile, the median, and the third
- 31 quartile. Whiskers denote the range of points within the first quartile 1.5× the interquartile
- 32 range and the third quartile + 1.5× the interquartile range.
- 33



34

35 Fig. 3 Patterns of tissue damage associated with COVID-19.

- 36 (A) The distribution of tissue-enhanced proteins across the major tissues affected by
- 37 COVID-19. Proteins whose expression altered in COVID-19 patients are colored red.
- 38 (B) Heatmap indicating expression patterns of known tissue specific biomarkers among
- 39 control, mild and severe patient groups.
- 40 (C) Systematic summary of brain-enhanced expressed proteins and signaling cascades
- 41 significantly altered in COVID-19 patients (neurotransmitters transport, synthesis). Values for
- 42 each protein at all analyzed samples (columns) are color-coded based on the expression
- 43 level, low (green) and high (red) z-scored FOT.
- 44 (D) Network summarizing lung-enhanced expressed proteins and signaling cascades
- 45 significantly altered in COVID-19 patients (HIF-1α signaling pathway).
- 46 (E) Network summarizing liver-enhanced expressed proteins and signaling cascades
- 47 significantly altered in COVID-19 patients (Lipid metabolism).
- 48 (F) Boxplot indicating the expression level of known brain dysfunctional biomarkers in
- 49 control, mild and severe patients.
- 50 (G) Heatmap showing normalized x-cell scores of specific cell types across control, mild and
- 51 severe COVID-19 patients. *p < 0.05 (t test).
- 52 (H) Heatmap showing the expression of cell type specific signatures among control, mild
- 53 and severe COVID-19 patients.
- 54 (I) Systematic summary of the GO pathways enriched by tissue-enhanced proteins that
- 55 exhibited altered expression among control, mild, and severe patient groups. The heatmap of
- 56 each panel indicates expression patterns of tissues-enhanced proteins among control, mild,

- 57 and severe patient groups. The fold changes in tissue-enhanced proteins between
- 58 mild/severe patient samples and control samples are shown on the right of heatmap.



60

61 Fig. 4 Differences in immune responses among COVID-19 patients.

- (A) Transcriptional profiles reflect the dynamic immune response in COVID-19. GSEA (FDR
 < 0.25; 1,000 permutations) was used to identify positive (red), negative (blue) or no (white)
 enrichment of BTMs (gene sets). The graph shows the normalized enrichment score (NES)
 of each selected BTM in the different time points (T1, T2 and T3) for patients with mild or
 severe COVID-19 illness, in comparison to healthy controls.
 (B) Expression levels of NETs' markers for individual transcripts in severe versus mild
- 68 comparisons. Data are represented as means \pm SEM, **p* < 0.05; ****p* < 0.001 (t test).

- 69 (C) Heatmap of *IFNG*, *GZMB* and *PRF1* gene expression in COVID-19 patients.
- 70 (D) Heatmap of genes enriched in IL-17 signaling pathway between healthy control and
- 71 COVID-19 patients.
- 72 (E) T cell and innate immune response elucidate immunopathology of COVID-19.
- 73



75

74

76 Fig. 5 COVID-19-associated metabolomic changes in blood plasma.

- (A) Plasma metabolomic changes revealed a trajectory in COVID-19 severity, from healthy
- control, mild, to severe.
- 79 (B) Changes in the concentration of plasma metabolites are associated with COVID-19
- 80 severity. The discharge group consist of all patients (mild and severe) that were recovered
- 81 and discharged.
- 82 (C) COVID-19 severity is associated with significant changes in lipoprotein subclasses

- 84 subclasses (LDL1, LDL4, LDL5), very low-density lipoprotein subclass-5 (VLDL5) and their
- 85 compositional components (ApoA1, triglycerides, cholesterol).
- 86 (D) Plasma levels of key enzymes and proteins directly involving lipoprotein metabolism are
- indicators for COVID-19 severity. *p < 0.05; **p < 0.01; ***p < 0.001 (t test). sLDLR: soluble
- 88 low density lipoprotein receptor; LCAT: lecithin-cholesterol acyltransferase; CEPT:
- 89 cholesteryl-ester transfer protein.
- 90 (E) COVID-19 caused dysregulation in lipoprotein metabolism, glycolysis and TCA cycle.
- 91 The three boxes from left to right are control, mild and severe, in which gray means normal,
- 92 blue means decrease, red means increase. H1: HDL1; H3: HDL3; H4: HDL4; L1: LDL1, L3:
- 93 LDL3; L4: LDL4; L5: LDL5; V1: VLDL1; V4: VLDL4; V5: VLDL5; TG: triglycerides; FC: free
- 94 cholesterol; CE: cholesteryl esters; CH: total cholesterol (i.e., FC + CE); PL: total
- 95 phospholipids; H4A1, H4A2: ApoA1 and ApoA2 in HDL4; H-A1, H-A2: ApoA1, ApoA2 (in
- 96 both HDL and nascent HDL); L1TG: TG in LDL1; L1%: LDL1 percentage in all LDL; TG%,
- 97 FC%, CE%: percentages of TG, FC and CE, respectively, in total lipids of given lipoprotein
- 98 subclasses; L-TG/L-CH: TG-to-CH ratio in LDL; H4CH/H4TG: CH-to-TG ratio in HDL4;
- 99 V1CH/V1TG: CH-to-TG ratio in VLDL1. CS: Citrate synthase; IDH: Isocitrate dehydrogenase;
- 100 ACO2: Aconitase; OGDH: α-ketoglutarate dehydrogenase; DLD: Dihydrolipoyl
- 101 dehydrogenase; SDH: Succinic dehydrogenase; MDH: Malate dehydrogenase; PDH:
- 102 Pyruvate dehydrogenase; PDK: Pyruvate dehydrogenase kinase; ACLY: ATP citrate lyase;
- 103 ACAC: Acetyl coenzyme A carboxylase; FASN: Fatty acid synthetase; LDH: Lactate

⁸³ including high-density lipoprotein subclass-1 (HDL1), HDL4, low-density lipoprotein

104 dehydrogenase.





- 108 (A) Bar plot comparison of viral loads between severe-survival patients and severe-fatal
- 109 patients. The cluster heatmap represents expression patterns of 1,541 proteins that exhibited
- 110 temporal changes across time points in severe-survival patients. Line graph represents the
- 111 temporal changes in viral load in time (days) after hospital admission of the patients.
- 112 (B) Enriched annotations for corresponding clusters showed in Fig. 6A.
- 113 (C-D) Systematic summary of proteins and signaling cascades significantly altered in severe-
- 114 survival patients (lipid metabolism; c) and severe-fatal (viral life cycle; d). Values for each
- 115 protein in all samples analyzed (columns) are color-coded based on the expression level, low
- 116 (blue) and high (red) z-scored FOT.
- 117 (E) For each of the four panels, the heatmaps on the left indicated the Pearson correlation of
- 118 proteins with viral load in severe survivors and severe fatalities, the heatmap on the right
- 119 indicated the significant pathways enriched by proteins positively or negatively correlated
- 120 with viral load in severe survivors and severe fatalities.



122

123 Fig. 7 Biomarkers predictive of clinical outcomes of COVID-19 patients.

(A) Principal component analysis of exRNA, transcriptome, proteome, and clinical covariate
 data from samples collected at the first timepoint. The first two components were used to
 describe the distribution of samples based on expressed genes, proteins and clinical data,

127 respectively, whereas the first and third components were used for samples based on the

- 128 exRNA data.
- 129 (B) Performance of prognostic models based on exRNA, transcriptome, proteome, and the
- 130 corresponding clinical covariate data sets. Model performance of the five-fold cross-
- 131 validation was assessed using the Matthews correlation coefficient (MCC), AUC, accuracy,
- 132 sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).
- 133 (C) The most frequently selected features of exRNA-, transcriptome-, proteome-, and
- 134 clinical-based models. Features were simultaneously identified from each of the four data
- 135 sets and for each of the four machine learning algorithms based on the frequency of

136 variables used by AI models during 50 runs of the five-fold cross-validation.

- 137 (D) Correlation heatmap among the most frequently selected features (frequency > 0.78)
- 138 used in the exRNA-based model. Members in the let-7 family selected for the exRNA-based
- 139 predictors (hsa-miR-98-5p, hsa-let-7a-5p, hsa-let-7d-5p, hsa-let-7f-5p) were highly correlated
- 140 with each other.
- 141 (E-I) Biomarkers identified from exRNA (E), transcriptome (F), proteome (H) and clinical data
- 142 (I) based models exhibited a clear separation between those patients with either good or
- 143 poor prognosis. (G) Functional enrichment of 110 protein features selected from random
- 144 forest modeling.